Application of Immunohistochemistry in Clinical Practices as a Standardized Assay for Breast Cancer.

IF 1.6 4区生物学 Q4 CELL BIOLOGY

Acta Histochemica Et Cytochemica Pub Date : 2023-02-28 DOI:10.1267/ahc.22-00050

Shinobu Masuda, Yoko Nakanishi

引用次数: 0

Abstract

Immunohistochemistry (IHC) has become an indispensable tool in the clinical practices for breast cancer; however, to achieve its standardization, numerous issues need to be overcome. In this review, we describe the development of IHC as an important clinical tool, and the challenges in standardizing IHC results for patients. We also present ideas for resolving the remaining issues and unmet needs, along with future directions.

Abstract Image

查看原文本刊更多论文

免疫组织化学作为乳腺癌标准化检测在临床实践中的应用。

免疫组织化学(IHC)已成为乳腺癌临床治疗中不可或缺的工具;然而，为了实现其标准化，需要克服许多问题。在这篇综述中，我们描述了免疫组化作为一种重要的临床工具的发展，以及标准化患者免疫组化结果的挑战。我们还提出了解决剩余问题和未满足需求的想法，以及未来的方向。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Acta Histochemica Et Cytochemica 生物-细胞生物学

CiteScore

3.50

自引率

8.30%

发文量

审稿时长

>12 weeks

期刊介绍： Acta Histochemica et Cytochemica is the official online journal of the Japan Society of Histochemistry and Cytochemistry. It is intended primarily for rapid publication of concise, original articles in the fields of histochemistry and cytochemistry. Manuscripts oriented towards methodological subjects that contain significant technical advances in these fields are also welcome. Manuscripts in English are accepted from investigators in any country, whether or not they are members of the Japan Society of Histochemistry and Cytochemistry. Manuscripts should be original work that has not been previously published and is not being considered for publication elsewhere, with the exception of abstracts. Manuscripts with essentially the same content as a paper that has been published or accepted, or is under consideration for publication, will not be considered. All submitted papers will be peer-reviewed by at least two referees selected by an appropriate Associate Editor. Acceptance is based on scientific significance, originality, and clarity. When required, a revised manuscript should be submitted within 3 months, otherwise it will be considered to be a new submission. The Editor-in-Chief will make all final decisions regarding acceptance.